Latest news with #STSS
Tokyo Weekender
4 days ago
- Health
- Tokyo Weekender
Japanese Scientists Develop Artificial Blood Compatible With All Blood Types
A critical component of healthcare, blood transfusions play a vital role in saving lives around the globe every day. Maintaining an adequate blood supply, though, is no easy task, particularly in low- and middle-income countries (LMIC). The demand for O – negative blood — the universal donor type — often exceeds supply and donations have a limited shelf life. Looking to address the issue are a group of Japanese scientists led by Hiromi Sakai at Nara Medical University . They've developed a new type of artificial blood that can be used in patients of any blood type. The artificial blood is created by extracting hemoglobin — a protein containing iron that facilitates the transportation of oxygen in red blood cells — from expired donor blood. It is then encased in a protective shell to create stable, virus-free artificial red blood cells. As these artificial cells have no blood type, there is no need for compatibility testing. The synthetic blood can reportedly be stored for up to two years at room temperature and five years under refrigeration. That is a significant improvement over donated red blood cells, which can only be stored under refrigeration for a maximum of 42 days . Artificial Blood Trials Small-scale studies began in 2022. Three groups of four healthy male volunteers aged 20 to 50 received a single intravenous injection of hemoglobin vesicles — artificial oxygen carriers that mimic the structure of red blood cells — in increasing amounts, up to 100 milliliters. While some participants experienced mild side effects, there were no significant changes in vital signs, including blood pressure. Building on that success, Sakai announced that his team was accelerating the process last July. In March, it started administering between 100 and 400 milliliters of the artificial blood cell solution to volunteers. If no side effects are confirmed, the trial will shift to examin ing the treatment's efficacy and safety. It aims to put the artificial red blood cells into practical use by around 2030. While these studies are taking place, Professor Teruyuki Komatsu of Chuo University's Faculty of Science and Engineering is also working on the development of artificial oxygen carriers, using albumin-encased hemoglobin to stabilize blood pressure and treat conditions like hemorrhage and stroke. So far, animal studies have shown promising results. As a result, researchers are now eager to move to human trials. Related Posts Japanese Researchers Develop Peptide To Counter COVID-19 Viruses 'Flesh Eating' STSS Infections Reach Record Numbers in Japan Eating Disorders on the Rise in Japan
Yahoo
25-04-2025
- Business
- Yahoo
Sharps Technology to effect 1-for-300 reverse stock split
Sharps Technology (STSS) will effect a 1-for-300 reverse stock split of its common stock, par value $0.0001 per share, that will become effective on April 27, 2025 at 11:59 PM Eastern Time, before the opening of trading on The Nasdaq Capital Market. Sharps has requested that its Common Stock begin trading on April 28, 2025, on a post-reverse split basis on the Nasdaq under the existing symbol 'STSS'. The reverse split is primarily intended to bring Sharps into compliance with the minimum bid price requirement for maintaining its listing on the Nasdaq. The new CUSIP number for the Common Stock following the reverse split will be 82003F309. Discover outperforming stocks and invest smarter with Top Smart Score Stocks. Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See Insiders' Hot Stocks on TipRanks >> Read More on STSS: Disclaimer & DisclosureReport an Issue Sharps Technology Urges Approval for Reverse Stock Split Sharps Technology reminds shareholders to vote 'FOR' reverse stock split 3 Penny Stocks to Watch Now, 3/11/25 Sharps Technology issues letter to shareholders Sign in to access your portfolio
